AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35316922
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 or 150 mg every 2 weeks for ≥ 3 to ≤ 30 months
Trial: 35317413
Drug: Tablet-based Tanzania
RxNorm normalized name: influenza A virus A/Tasmania/503/2020 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based Tanzania 24-hour recall tool (TZ-24hr-DR)
Trial: 35317851
Drug: SCONE™ therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCONE™ therapy (transcutaneous spinal cord neuromodulation)
Trial: 35318970
Drug: Gadopiclenol at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadopiclenol at a dose of 0.05 mmol/kg
Trial: 35319502
Drug: Opioids coprescribed
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids coprescribed with antidepressants interacting with CYP2D6
Trial: 35319502
Drug: Predicted phenotypes
RxNorm normalized name: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype
DrugBank: DCP-001 (DB17423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted phenotypes and drug-drug interactions
Trial: 35320878
Drug: Myosuit (robotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myosuit (robotic assistance) during activities of daily life (ADL)
Trial: 35320878
Drug: No robotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No robotic assistance during activities of daily life (ADL)
Trial: 35321427
Drug: Dalpiciclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (125 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Trial: 35321427
Drug: Dalpiciclib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (100 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Trial: 35321427
Drug: Dalpiciclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (125 mg), Pyrotinib (320 mg), Letrozole (2.5 mg)
Trial: 35321427
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment (1L HER2-targeted therapy)
Trial: 35321427
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment (2L HER2-targeted therapy)
Trial: 35321427
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment (2L setting)
Trial: 35321744
Drug: Somatocognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatocognitive therapy (SCT)
Trial: 35321744
Drug: Standard PVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PVD treatment
Trial: 35321895
Drug: Pfizer BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer BNT162b2 mRNA COVID-19 vaccine, 1 dose, administered within 4 days of enrolment
Trial: 35322287
Drug: Copanlisib 60
RxNorm normalized name: copanlisib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib 60 mg intravenous infusion on days 1, 8, and 15 of a 28-day cycle
Trial: 35322330
Drug: Contact Force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact Force (CF) > 25 g
Trial: 35322535
Drug: Ready-to-use room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use room temperature liquid stable formulation of glucagon
Trial: 35322535
Drug: Lyophilised formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilised formulation of glucagon
Trial: 35323379
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Social Skills Training (CBSST) with intranasal oxytocin
Trial: 35323885
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention (oral and written education about LB)
Trial: 35323905
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral dydrogesterone (DYD) ter-in-die (tid) for luteal support
Trial: 35323932
Drug: Clinical prediction
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical prediction model containing soluble urokinase plasminogen activator receptor (suPAR)
Trial: 35324095
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antipsychotic treatment)
Trial: 35325211
Drug: JNJ-74699157 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-74699157 (100 mg)
Trial: 35325211
Drug: JNJ-74699157 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-74699157 (200 mg)
Trial: 35325225
Drug: Lenvatinib (MTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (MTD 24 mg) with capecitabine-based chemoradiation
Trial: 35326718
Drug: TTFields/sorafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFields/sorafenib (150 kHz for ≥18 h/day with sorafenib 400 mg BID)
Trial: 35331504
Drug: Nutrition-focused quality
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition-focused quality improvement program (QIP) including education on macro- and micronutrient intake and physical exercise, dietary counseling, and provision of oral nutritional supplements (ONS) for daily intake over 60 days.
Trial: 35331634
Drug: Vestronidase alfa
RxNorm normalized name: Vestronidase alfa
DrugBank: Vestronidase alfa (DB12366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks
Trial: 35332036
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation (radiosurgery) targeting the retroperitoneal coeliac plexus nerve bundle with a single fraction of 25 Gy
Trial: 35332134
Drug: Antidepressant (escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (escitalopram 20 mg/day)
Trial: 35332134
Drug: Antidepressant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant plus COX-2 inhibitor (celecoxib)
Trial: 35332278
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) therapy, median 4.0 cycles (range, 1-20)
Trial: 35332278
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) therapy
Trial: 35332334
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of COVID-19 vaccine
Trial: 35332334
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of COVID-19 vaccine
Trial: 35332334
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of COVID-19 vaccine
Trial: 35332334
Drug: Full vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full vaccination (two doses)
Trial: 35333110
Drug: AAVrh10 or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAVrh10 or AAV9 (systemic or CSF administration)
Trial: 35337339
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of famitinib (angiogenesis inhibitor), camrelizumab (PD-1 monoclonal antibody), and chemotherapy
Trial: 35337339
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of famitinib, camrelizumab, and chemotherapy
Trial: 35337388
Drug: Multimodal physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal physical therapy program (manual therapy, therapeutic exercise, static progressive splinting) over 4 weeks
Trial: 35337388
Drug: Manipulation under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manipulation under anesthesia followed by physical therapy
Trial: 35337972
Drug: Abemaciclib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib + Endocrine Therapy (ET)
Trial: 35384873
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy (ET) alone
Trial: 35338252
Drug: Average total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average total fluid administration (TFA) > 150 mL/kg birthweight/day
Trial: 35338773
Drug: CD19-specific CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-specific CAR T cell-based therapy
Trial: 35340685
Drug: nCRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCRT with a total dose of 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus 45 Gy in 25 fractions on the whole pelvis, with continuous oral capecitabine chemotherapy.
Trial: 35341327
Drug: Evidence-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatments
Trial: 35341613
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for addiction treatment (MAT)
Trial: 35341724
Drug: Radial wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial wave therapy (RW group) - 6 weekly sessions
Trial: 35341724
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (control group) - 6 weekly sessions
Trial: 35341724
Drug: Radial wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial wave therapy (RW group)
Trial: 35341952
Drug: Rectal expulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal expulsion device (RED)
Trial: 35342321
Drug: E-GPS (Glasgow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-GPS (Glasgow prognostic score after first-line chemotherapy)
Trial: 35342822
Drug: ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranibizumab (0.5 or 2.0 mg) monthly or as-needed (PRN) for 24 months
Trial: 35343187
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg for six cycles or until disease progression or unacceptable toxicity or withdrawal
Trial: 35343910
Drug: PEAR-004, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEAR-004, a smartphone-based investigational digital therapeutic, added to standard treatments for schizophrenia.
Trial: 35344040
Drug: Venetoclax as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax as a monotherapy
Trial: 35345248
Drug: DAPT (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (dual antiplatelet therapy)
Trial: 35345248
Drug: PCI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI treatment
Trial: 35346070
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) with yttrium-90, target mean dose to tumor is ≥ 150 Gy.
Trial: 35346070
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) with yttrium-90
Trial: 35346165
Drug: Moderate albuminuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate albuminuria (UACR 30-300 mg/g)
Trial: 35346165
Drug: Severe albuminuria
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe albuminuria (UACR > 300 mg/g)
Trial: 35346219
Drug: Opioid Medication
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Medication Therapy (OMT)
Trial: 35347559
Drug: Glesatinib 700
RxNorm normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glesatinib 700 mg twice daily (micronized V2) with erlotinib 150 mg once daily
Trial: 35347559
Drug: Glesatinib 700
RxNorm normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glesatinib 700 mg twice daily (micronized V2) with docetaxel 75 mg/m2
Trial: 35347559
Drug: Glesatinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glesatinib (various formulations) plus erlotinib or docetaxel
Trial: 35348754
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg orally daily)
Trial: 35349331
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg/m) added to conventional AML chemotherapy
Trial: 35349331
Drug: Conventional AML
RxNorm normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional AML chemotherapy
Trial: 35349491
Drug: CIML NK
RxNorm normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIML NK cells infused after lymphodepleting chemotherapy (5 to 10 million cells/kg) followed by systemic IL-2 for 7 doses.
Trial: 35349683
Drug: Marine oil
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine oil supplement (2 g/d for 28-30 days)
Trial: 35350834
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of the COVID-19 vaccine
Trial: 35350834
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of the COVID-19 vaccine
Trial: 35350834
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of the COVID-19 vaccine
Trial: 35351181
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of p-tau217 with hippocampal volume, cognition, and APOE genotype
Trial: 35351181
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of p-tau217 and cognition
Trial: 35351214
Drug: Restrictive intravenous
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive intravenous fluid protocol
Trial: 35352097
Drug: Electronic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic dose monitoring (EDM) for ART adherence
Trial: 35352102
Drug: Daily coformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily coformulated tenofovir disoproxil fumarate and emtricitabine for HIV prevention
Trial: 35352313
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg every 4 or 8 weeks
Trial: 35352512
Drug: sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab (200 mg IV every 2 weeks for three cycles) plus hypofractionated radiotherapy (5 Gy × 5)
Trial: 35352766
Drug: Albuterol and
RxNorm normalized name: Albuterol and cromolyn only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol and ipratropium bromide delivered via pressurized metered-dose inhaler with holding chamber and systemic corticosteroids
Trial: 35353154
Drug: Dual pathway
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual pathway inhibition (DPI) with a P2Y12 inhibitor (clopidogrel or ticagrelor) and a vascular dose of rivaroxaban
Trial: 35353154
Drug: DAPT with
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT with a P2Y12 inhibitor (clopidogrel or ticagrelor)
Trial: 35353219
Drug: IDH305 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDH305 at doses 75-750 mg twice daily
Trial: 35353263
Drug: Drug switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug switching
Trial: 35353263
Drug: MASES and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MASES and BASMI scores in drug switchers
Trial: 35353962
Drug: Primaquine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine at a total dose of 7.0 mg per kilogram
Trial: 35354274
Drug: Avelumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, dosage not specified, duration not specified
Trial: 35354808
Drug: Devimistat in
RxNorm normalized name: Devimistat
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Devimistat in combination with high dose cytarabine and mitoxantrone
Trial: 35355447
Drug: Daprodustat (6-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat (6-mg single dose)
Trial: 35355714
Drug: Psilocybin (medium-high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (medium-high doses)
Trial: 35355991
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of melatonin and DADA (diisopropylamine dichloroacetate)
Trial: 35355991
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of melatonin and DADA
Trial: 35356197
Drug: CD19-CAR T
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-CAR T cell therapy (tisagenlecleucel or on an institutional clinical trial)
Trial: 35356225
Drug: Conventional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional surgical treatment group (Group B)
Trial: 35356262
Drug: Pyrotinib-based therapy
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib-based therapy
Trial: 35357027
Drug: Dostarlimab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (1, 3 or 10 mg/kg)
Trial: 35357325
Drug: Mindfulness mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness mobile application (Headspace) used daily for 30 days (up to 10 minutes a day)
Trial: 35358443
Drug: Index therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index therapies included immunochemotherapy (n=133)
Trial: 35358443
Drug: Index therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index therapies included anti-CD20 antibody monotherapy (n=53)
Trial: 35358443
Drug: Index therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index therapies included lenalidomide with or without anti-CD20 (n=37)
Trial: 35358443
Drug: Index therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index therapies included phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25)
Trial: 35358810
Drug: Baseline phenotypic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline phenotypic measurements (e.g., patient global estimate of health status, 6-min walk distance, HRQoL measures)
Trial: 35359000
Drug: Atezolizumab (atezo)
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (atezo) with obinutuzumab (G) and bendamustine
Trial: 35359899
Drug: Investigational Medicinal
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product (IMP) - Molecular radiotherapy (details on dosage and duration not available)
Trial: 35360218
Drug: ICP-directed treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-directed treatment
Trial: 35360224
Drug: Autonomic Regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic Regulation Therapy (ART) using chronic vagus nerve stimulation (VNS)
Trial: 35361185
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy aimed at stabilizing the hip joint
Trial: 35361185
Drug: Arthroscopic plication
RxNorm normalized name: MANGANESE DICATION
DrugBank: Manganese cation (DB06757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic plication of the hip joint capsule
Trial: 35361487
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered intravenously Q3W for up to 35 cycles (approximately 2 years)
Trial: 35361691
Drug: Third SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third SARS-CoV-2 vaccine
Trial: 35362857
Drug: Steroid use
RxNorm normalized name: Antiinflammatory preparations, non-steroids for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid use in the second wave
Trial: 35362862
Drug: Low-dose estrogen/progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose estrogen/progestin (LEP)